𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Quantitative analysis of antibodies to hepatitis C virus during interferon-α therapy

✍ Scribed by Nobukazu Yuki; Norio Hayashi; Hideki Hagiwara; Tetsuo Takehara; Kazuhiro Katayama; Akinori Kasahara; Hideyuki Fusamoto; Takenobu Kamada

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
598 KB
Volume
17
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

W e quantified IgG antibodies to structural (core) and nonstructural (C100-3) hepatitis C virus proteins in 42 patients with chronic hepatitis C treated with a 6-mo course of interferon-a. Sera were drawn before and at the end of therapy and also 6 mo after therapy withdrawal; they were stored for later analysis of antibodies and serum hepatitis C virus RNA. Sustained virus clearance was observed at the end of therapy and 6 mo after therapy withdrawal in nine cases; it was accompanied with sustained reductions of antibody to hepatitis C virus core protein and antibody to C100-3 protein. A sustained reduction of antibody to hepatitis C virus core protein was specific to sustained virus clearance, although that of antibody to C 100-3 protein was not. None of the patients who did not show reductions of levels of both antibodies at the end of therapy displayed sustained virus clearance. Five patients showed hepatitis C virus RNA negativity and normal aminotransferase levels at the end of therapy without reduction of antibody to hepatitis C virus core protein levels. Of these five patients, relapse of hepatitis occurred in four, and viremia was present 6 mo after therapy withdrawal in all cases. These results demonstrate that testing for antibody titers may add information for evaluating virus clearance after interferon therapy. (HEPATOLOGY 1993; 11960-965.)

📜 SIMILAR VOLUMES

Factors predictive of response to interf
Factors predictive of response to interferon-α therapy in hepatitis C virus infection
✍ Akihito Tsubota; Kazuaki Chayama; Kenji Ikeda; Arase Yasuji; Isao Koida; Satoshi 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 759 KB

To determine the patient-dependent and virusrelated factors that may predict sustained response to interferon-a therapy, we prospectively evaluated 60 consecutive patients with chronic hepatitis C who received a standardized treatment schedule of interferon-a. Twenty-eight patients achieved a long-t

Changes in antibody titers to hepatitis
Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection
✍ MD Akihiko Urushihara; Takeshi Sodeyama; Akihiro Matsumoto; Eiji Tanaka 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 804 KB

## Abstract The use of quantitative assays for hepatitis C virus specific antibodies (anti‐HCV) as a prognostic marker was evaluated in 31 patients with chronic hepatitis C treated with interferon (IFN). Changes in titers of serum HCV‐RNA and anti‐HCV antibodies; anti‐C11 (anti‐core), anti‐C100 (an

Detection of hepatitis C virus by polyme
Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus
✍ Kentaro Yoshioka; Shinichi Kakumu; Takaji Wakita; Tetsuya Ishikawa; Yuji Itoh; M 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 744 KB

To investigate the relationship between genotypes of hepatitis C virus and response to interferon-a therapy, hepatitis C virus RNA was assayed by polymerase chain reaction with three sets of primers and probes in 70 patients with non-A, non-B chronic hepatitis who received interferon-a. Twenty-four

Quantitative analysis of antibody to hep
Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection
✍ N Yuki; N Hayashi; A Kasahara; H Hagiwara; E Mita; K Ohkawa; K Katayama; H Fusam 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 2 views

The significance of circulating antibody to hepatitis C HCV E1 corresponds to the pestiviral gp33/gp25 envevirus (HCV) envelope glycoprotein 2 (E2)/nonstructural lope glycoprotein and the flaviviral envelope protein protein 1 (NS1) glycoprotein was studied in 83 patients (M/E), whereas E2/NS1 corres

Pegylated interferon α therapy in acute
Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics
✍ Sanaa M. Kamal; Alaa Ismail; Camilla S. Graham; Qi He; Jens W. Rasenack; Thomas 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB

Pegylated interferon ␣ (PEG IFN-␣) improves sustained virological response rates in chronic hepatitis C, but neither its role in acute hepatitis C nor the biologic basis for its action has been defined. This prospective study assessed the efficacy of PEG IFN-␣ treatment in acute hepatitis C in relat

Factors predictive of response to interf
Factors predictive of response to interferon-α therapy in hepatitis C virus type 1b infection
✍ Byung-Il Yeh; Kwang-Hyub Han; Hyean-Woo Lee; Joon Hyung Sohn; Wang-Shick Ryu; Do 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

## Abstract Interferon‐α (IFN‐α) has been used to treat hepatitis C Virus (HCV)‐induced infection but has been effective in only about half of all patients. It is suggested that the different responses to IFN‐α treatment in HCV infection may be influenced by HCV genotypes, HCV RNA titer at the begi